Table 1.
Categories of vaccines and immunotherapeutic studies in Phase 2 or Phase 3 trial
| Immunotherapeutic and vaccine studies under investigation | |||||
|---|---|---|---|---|---|
| Vaccine category | Phase 2 | Phase 2/3 | Phase 3 | Totala | Ratio of Phase 3:Phase 2b |
| Peptide-based | 93 | 1 | 18 | 112 | 1:19 |
| Dendritic cell-based | 74 | 3 | 11 | 88 | 1:15 |
| Tumour cell-based | 64 | 3 | 11 | 78 | 1:17 |
| Virus-based | 46 | 1 | 5 | 52 | 1:11 |
| Protein-based | 19 | 1 | 12 | 32 | 1:63 |
| Anti-idiotypic antibody | 18 | 1 | 9 | 28 | 1:50 |
| Others | 21 | 2 | 5 | 28 | 1:24 |
| T cell-based | 12 | 1 | 13 | 1:8 | |
| DNA-based | 8 | 2 | 10 | 1:25 | |
| Bacterial-based | 2 | 1 | 3 | 1:50 | |
| PBMC-based | 2 | 2 | NA | ||
| VLP-based | 2 | 2 | NA | ||
| Yeast-based | 2 | 2 | NA | ||
| RNA-based | 1 | 1 | NA | ||
| Grand Total | 364 | 12 | 75 | 451 | 1:21 |
aSorted by prevalence
bratio of phase 3 trials: phase 2 trials